Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere
Genmab releases new phase 2 data for its antibody-drug conjugate, prompting claims of superiority over rival treatments.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
Genmab announced Phase 2 results for Rinatabart Sesutecan showing durable and clinically meaningful responses in patients with platinum-resistant ovarian cancer. The data strengthened the case for the company's ProfoundBio acquisition and spurred claims that the antibody-drug conjugate is clearly superior to AbbVie's Elahere.
Epilogue added 38d ago, after coverage quieted.
The brief
Recent coverage details new phase 2 clinical trial results released by Genmab concerning its antibody-drug conjugate, known as Rinatabart Sesutecan or Rina-S. According to reporting from Business Wire and Fierce Biotech, the RAINFOL-01 trial evaluated Rina-S in patients diagnosed with platinum-resistant ovarian cancer. Endpoints News and The Pharma Letter note that the data demonstrate durable and clinically meaningful responses, with TradingView reporting an overall response rate of forty-five point nine percent. European Biotechnology Magazine highlights that these findings strengthen the case for Genmab's prior financial investment, specifically pointing to an eighteen-hundred-million-dollar bet on ProfoundBio. The emerging conversation in the trades also draws direct comparisons between Genmab's product and existing therapies in the same space.
Fierce Biotech's coverage brings attention to claims suggesting the antibody-drug conjugate is clearly superior to AbbVie's Elahere. Additional reporting from Endpoints News links the Genmab data release with unrelated regulatory updates, such as label expansions for Eli Lilly's Jaypirca. Outlets like TradingView have categorized these announcements within weekly market recaps, which also touch upon unrelated corporate developments such as Darwin Global's voting control metrics. Context provided across the reporting sources emphasizes the high stakes within the oncology therapeutics market, particularly regarding treatments for platinum-resistant ovarian cancer. Coverage does not yet specify the full timeline for subsequent regulatory submissions or upcoming late-stage trial milestones, leaving open questions about how quickly Genmab plans to advance the drug toward commercialization or pivotal review stages.
Observers tracking the sector are looking toward upcoming medical congress presentations and corporate updates from Genmab for further details on the Rina-S program. Business Wire and other specialized outlets indicate that future disclosures will likely provide deeper dives into safety profiles, progression-free survival data, and comparative analyses with competing therapies like Elahere. Coverage does not yet specify whether regulatory authorities have granted any expedited review statuses or when the formal trial completion date will be officially reached.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (93% supported) Updated 40d ago.
Quick answers
What is the name of Genmab's antibody-drug conjugate?
It is called Rinatabart Sesutecan, also referred to as Rina-S.
Which cancer indication was evaluated in the recent data release?
The RAINFOL-01 trial evaluated patients with platinum-resistant ovarian cancer.
What comparison is being made regarding competitor products?
Industry coverage features claims that Genmab's ADC is clearly superior to AbbVie's Elahere.
Coverage (6)
- Genmab’s Phase 2 data strengthens case for $1.8B ProfoundBio bet European Biotechnology Magazine · 43d ago
- Genmab details ovarian cancer data; Lilly’s Jaypirca gets a label expansion Endpoints News · 43d ago
- Weekly Recap: Rina‑S 45.9% ORR and Darwin Global 5.11% voting control TradingView · 43d ago
- Genmab’s Rina-S shows durable responses in ovarian cancer The Pharma Letter · 43d ago
- Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer Business Wire · 43d ago
- Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere Fierce Biotech · 43d ago
Topics
Related trends
AbbVie’s next-gen Crohn’s disease combo beats Skyrizi in phase 2 trial
AbbVie presents phase 2 trial data for its next-generation Crohn's disease therapy, ABBV-466.
After $10.9B exit to AbbVie, Apogee execs join Paragon to scale its R&D, company creation engine
Former Apogee executives join Paragon Labs to scale R&D following an acquisition, while Alaunos Therapeutics secures major financing.
AbbVie's Cerevel buyout delivers as FDA gives go-ahead to 1st-in-class Juvmo in Parkinson's disease
The FDA has approved Juvmo, a first-in-class Parkinson's disease medication, validating AbbVie's $8.7 billion acquisition of Cerevel.
New Parkinson’s drug approved in the US: What does it do differently?
The U.S. FDA has approved AbbVie's Juvmo, a first-in-class medication designed to provide a next-generation treatment option for Parkinson's disease.
AbbVie Revenue Rises on Strength in Immunology, Neuroscience
AbbVie reports Q3 2026 sales performance aligned with analyst estimates, driven by growth in its immunology and neuroscience portfolios.
Genmab Stock Surges to Record High as Cancer Drug Slashes Risk of Death by 50%
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.